Christopher A. Viehbacher
Christopher A. Viehbacher is chief executive officer of Sanofi, where he is also a board member and a member of the Strategic Committee. He is also the chairman of Genzyme, which Sanofi acquired in February 2011.
After beginning his career in finance at PriceWaterhouseCoopers, Mr. Viehbacher joined Glaxo-SmithKline in 1988. Throughout 20 years with that company, he acquired broad international experience in Europe, the United States, and Canada. His last position there, before joining Sanofi, was president of pharmaceutical operations North America. He was also a member of the board and cochairman of the Portfolio Management Board.
Mr. Viehbacher is a former chairman of PhRMA in the United States and is currently the chair of the CEO Roundtable on Cancer. This association brings together employers from across the United States to develop workplace initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to treatment, and hasten the discovery of diagnostic tools and anti-cancer therapies.
In 2003, the French government acknowledged Mr. Viehbacher's commitment to public health and business by naming him a knight of the French Legion of Honor. He also received the 2012 Pasteur Foundation Award, recognizing his leadership role in the pharmaceutical industry's support of research and development and improving the health of people around the world.
Mr. Viehbacher is a member of the International Business Council and a member of the Board of Visitors of the Fuqua School of Business at Duke University. He is a graduate of Queen's University in Ontario, Canada, and a certified public accountant.